association

Full identifier: http://purl.org/np/RA1343SbM4Wqjs8cyjrcWdsI1OZCIog8tty3jmM1UJF7A#association

Assigned to 1 class:

Minted in Nanopublication

 RA1343SbM4 comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RA1343SbM4... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-08-23T19:14:26.265+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA1343SbM4... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .
This is the identifier for this whole nanopublication. http://purl.org/np/RA1343SbM4... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA1343SbM4... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T17:14:26.265Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
"* Medullary Thyroid Carcinoma VICTOZA is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). * Hypersensitivity VICTOZA is contraindicated in patients with a prior serious hypersensitivity reaction to VICTOZA or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with VICTOZA [see Warnings and Precautions 5.6 VICTOZA is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4) VICTOZA is contraindicated in patients with a prior serious hypersensitivity reaction to VICTOZA or any of the product components (4)"
Leoni Bücken
2021-08-23T17:14:26.265Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T17:14:26.265Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T17:14:26.265Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T17:14:26.265Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T17:14:26.265Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-08-23T17:14:26.265Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)